Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04569032
Title A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seagen Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | GBR | FRA | ESP | CZE


No variant requirements are available.